Ten COVID-19 vaccines could be available by mid-next year if they receive regulatory approval, but their inventors need patent protection, the global group leader said on Friday. pharmaceutical industry. Pfizer and BioNtech, as well as Moderna and AstraZeneca, have shown promising results in large clinical trials, but there is no question of “cutting corners,” said Thomas Cueni, International Federation of Pharmaceutical Industries Associations and Manufacturers (IFPMA).
This news content is a computer generated summarized version of the original article and the authenticity of the original content has not been verified. Please click on the View Article button to refer to the actual content.